The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120
- 1 December 2009
- Vol. 28 (2) , 352-360
- https://doi.org/10.1016/j.vaccine.2009.10.040
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of Veterans Affairs, the New York University Center for AIDS Research Immunology Core (AI-27742)
- NIH (AI-48371)
This publication has 47 references indexed in Scilit:
- Worldwide Distribution of HIV Type 1 Epitopes Recognized by Human Anti-V3 Monoclonal AntibodiesAIDS Research and Human Retroviruses, 2009
- Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 InfectionJournal of Virology, 2009
- Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected IndividualsJournal of Virology, 2009
- Human Immunodeficiency Virus Type 1 Superinfection Occurs despite Relatively Robust Neutralizing Antibody ResponsesJournal of Virology, 2008
- Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and CJournal of Virology, 2008
- Viral complementation allows HIV-1 replication without integrationRetrovirology, 2008
- In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120Virology, 2008
- Removal of a Single N-Linked Glycan in Human Immunodeficiency Virus Type 1 gp120 Results in an Enhanced Ability To Induce Neutralizing Antibody ResponsesJournal of Virology, 2008
- Structural Basis for Coreceptor Selectivity by The HIV Type 1 V3 LoopAIDS Research and Human Retroviruses, 2007
- Factors Determining the Breadth and Potency of Neutralization by V3-Specific Human Monoclonal Antibodies Derived from Subjects Infected with Clade A or Clade B Strains of Human Immunodeficiency Virus Type 1Journal of Virology, 2006